Adam Sperling
@adamssperling
Followers
841
Following
913
Media
17
Statuses
876
Physician scientist @BrighamHeme and @DFCI. Former @BrighamMedRes. Heme malignancy. Clonal hematopoiesis. Multiple myeloma. Live in Boston but root for LA.
Massachusetts, USA
Joined October 2010
Cannot recommend this lab highly enough.
I am very excited to announce that I have started my lab at the Brigham and Women’s Hospital and Harvard Medical School in the Department of Pathology. We are seeking talented, curious, individuals and recruiting at all levels! https://t.co/rXEcDwQsPS 1/2
0
1
3
📢 excited to announce that our clinical research on EASIX & post-CAR-T complications & outcomes has been published in @jitcancer This study offers further insights into potential biomarkers for better risk stratification & toxicity management. #mmsm
1
6
9
Laurie H. Glimcher, MD, Dana-Farber’s transformative President and CEO, announced today that she will step down on October 1, 2024, and will assume the title of President Emerita. Benjamin Levine Ebert, MD, PhD, chair of Department of Medical Oncology and a world-renowned
3
20
71
Excited to share our paper in @NatureBiotech. We've developed a CAR-Enhancer (CAR-E) that enhances the activity and persistence of CAR T-cells. These memory CAR T-cells can re-expand months later. Here's a brief summary:
10
27
115
Endogenous polymerization of BTB domains: Our initial hypothesis was that this would lead to protein degradation, but instead, polymerization led to enhanced chromatin binding at homotypic clusters, causing transcriptional repression. Great story spearheaded by amazing Park Team!
Excited to share our story on polymerization in ZBTB transcription factors, which was published in the July 11 issue of @MolecularCell! https://t.co/qlzxfF0PR4 1/n
0
1
26
Am certainly sad to see him leave but sounds like an amazing opportunity. Congrats Jens!
We will miss Jens @DanaFarber but we look forward to what he does with this fantastic opportunity and new role.
1
0
2
A potential disaster for patients with cancer if such a major budget cut happens. Cancer clinicians and researchers need to speak up in all ways possible on behalf of our patients.
After a year of lean appropriations, @theNCI is looking at what threatens to be a budgetary cataclysm—a potential 10-11% cut to the Labor-HHS spending bill in fiscal year 2025. https://t.co/JpIHkrY97T
0
10
20
Newly open application for the Advanced Fellowship in Leukemia @DanaFarber. Led by @LuskinMarlise Please share.
3
27
62
New IMS high risk definition for multiple myeloma presented by Prof Corre @COMyCongress . Fantastic effort by co-operative groups to redefine risk. Clearly an evolving area.
3
37
86
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients w... https://t.co/FQyMcPwx0W Sharing our experience with a Quad in #mmsm @betsyodonnellmd @andrew02114 @MGHCancerCenter
0
6
21
We are looking for a couple of Research Technicians to join us in the @fischerlab1! If you enjoy biochemistry/chem bio and are interested in working in a great team exploring degrader induced interactions and degradation reach out or apply: https://t.co/JTgH6CfuUA Please RT!
2
18
29
Getting MRD as an endpoint was a great partnership between academia and industry and patient organization. A model to follow. Patients are three winner. @VincentRK #@NoopurRajeMD #myelomasociety
10
24
102
MRD as an official endpoint for accelerated approval ODAC votes 12-0 great work by all congratulations!!
3
26
83
IFYKYK … two of the true OGs of #BMT catching the eclipse and looking good doing it @DanaFarber @romeerizwan @MGooptu @DrCCutler
4
3
42
Congratulations to my former Broadie and DFCI colleagues for their induction as 2024 @AACR Fellows #AACR24 @broadinstitute @DanaFarber . Well deserved.
0
3
15
Congrats @AlexSilverMSTP. Very nice work.
TET2 clonal hematopoiesis is enriched among individuals receiving solid organ transplantation. While this didn't predict transplant outcomes, whether it plays a role in the ultimate transplant indication requires further study https://t.co/1axLKJ50Nq
@AACR @AlexSilverMSTP
0
0
1
@IrenemGhobrial presenting data and rationale of early use of immunotherapy in patients with HR-SMM at the IMS Immune Therapies Meeting @Myeloma_Society @DanaFarber #mmsm
0
5
11
So many unknowns about carfilzomib in #MMsm around the 🌎 - help tell us what you do! Link below for any oncologist treating myeloma: 12 q's, <3 min. Thank you! https://t.co/EjLgfRgG2Z cc @GKaurMD @VincentRK @gjmccaughan @DrNikitaMehra @adamssperling @BoWangMD1 and more!
0
9
12